Author

A. M. Unni

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Approach:experimental assay· 1 Assay:whole-exome sequencing· 1

Frequent Co-Authors

D. A. Farnsworth· 1 shared D. Lu· 1 shared F. D. Johnson· 1 shared G. de Rappard-Yuswack· 1 shared H. Varmus· 1 shared M. Ladanyi· 1 shared R. Shi· 1 shared R. Somwar· 1 shared

Activity by Year

2016-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

D. A. Farnsworth

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

MEK inhibitor resistance in lung cancer cells associated with addiction to sustained ERK suppression

D. A. Farnsworth, Y. Inoue, F. D. Johnson, G. de Rappard-Yuswack, D. Lu, R. Shi, R. Somwar, M. Ladanyi, A. M. Unni, W. Lockwood

The paper identifies drug addiction to MEK inhibitors in KRAS-mutant lung cancer cells, showing that resistance is linked to ERK suppression and KRAS amplification, suggesting therapeutic strategies involving drug holidays.

bioRxiv · Apr 29, 2022 · PreprintCancer Biology

How Cancer Genomics Drives Cancer Biology: Does Synthetic Lethality Explain Mutually Exclusive Oncogenic Mutations?

H. Varmus, A. M. Unni, W. W. Lockwood

The paper investigates mutual exclusivity of KRAS and EGFR mutations in lung adenocarcinomas, suggesting synthetic lethality explains their absence in co-occurring tumors.

bioRxiv · Dec 18, 2016Cancer Biology